Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Lucy Scientific Discovery Inc. (LSDIF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/25/2025: LSDIF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.29% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/25/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.00M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -37.69 | 52 Weeks Range 0.00 - 0.50 | Updated Date 05/10/2025 |
52 Weeks Range 0.00 - 0.50 | Updated Date 05/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8906.54% |
Management Effectiveness
Return on Assets (TTM) -99.35% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2002470 | Price to Sales(TTM) 0.02 |
Enterprise Value 2002470 | Price to Sales(TTM) 0.02 | ||
Enterprise Value to Revenue 119.68 | Enterprise Value to EBITDA -9.52 | Shares Outstanding 1764760 | Shares Floating 1460178 |
Shares Outstanding 1764760 | Shares Floating 1460178 | ||
Percent Insiders 18.03 | Percent Institutions - |
Upturn AI SWOT
Lucy Scientific Discovery Inc.
Company Overview
History and Background
Lucy Scientific Discovery Inc. (LSDI) was incorporated in 2021. It focuses on the manufacturing of pharmaceutical-grade cannabinoid APIs and psychedelics. The company operates within the evolving landscape of pharmaceutical cannabinoid and psychedelic compounds.
Core Business Areas
- Pharmaceutical-Grade Cannabinoid APIs Manufacturing: Focuses on the production of cannabinoid Active Pharmaceutical Ingredients (APIs) that meet pharmaceutical standards.
- Psychedelics: Manufacturing of pharmaceutical-grade psychedelics.
Leadership and Structure
The leadership structure includes a CEO and a board of directors. Specific details about the team composition are best obtained directly from the company's website or regulatory filings.
Top Products and Market Share
Key Offerings
- Pharmaceutical-Grade Cannabinoid APIs: Active pharmaceutical ingredients derived from cannabinoids, targeting pharmaceutical companies for research and drug development. Market share data is currently unavailable. Competitors include companies specializing in cannabinoid API manufacturing.
- Psychedelics: Active pharmaceutical ingredients derived from psychedelic drugs, targeting pharmaceutical companies for research and drug development. Market share data is currently unavailable. Competitors include companies specializing in psychedelic API manufacturing.
Market Dynamics
Industry Overview
The cannabinoid and psychedelic API market is growing, driven by increasing research into therapeutic applications and evolving regulatory frameworks.
Positioning
Lucy Scientific Discovery Inc. aims to be a key player in the manufacturing and supply of pharmaceutical-grade cannabinoid and psychedelic APIs. Its competitive advantage lies in its manufacturing capabilities, quality standards and regulatory compliance. However the industry is fragmented and still developing.
Total Addressable Market (TAM)
The TAM for pharmaceutical-grade cannabinoid and psychedelic APIs is projected to grow significantly in the coming years, however specific numbers are difficult to verify. Lucy Scientific Discovery Inc. is positioned to capture a share of this growing market through its focus on quality and compliance. No official guidance given.
Upturn SWOT Analysis
Strengths
- Specialized manufacturing capabilities
- Focus on pharmaceutical-grade quality
- Early mover advantage in a nascent market
Weaknesses
- Limited operating history
- Small Market Cap
- High dependence on regulatory approvals
- Financial instability
Opportunities
- Expanding research into cannabinoid and psychedelic therapies
- Evolving regulatory landscape favoring licensed manufacturers
- Strategic partnerships with pharmaceutical companies
Threats
- Competition from larger pharmaceutical companies
- Changes in regulations impacting cannabinoid and psychedelic products
- Market acceptance of cannabinoid and psychedelic therapies
- Financing risks.
Competitors and Market Share
Key Competitors
- Cronos Group (CRON)
- Canopy Growth Corporation (CGC)
- Aurora Cannabis (ACB)
Competitive Landscape
Lucy Scientific Discovery Inc. faces competition from established players in the cannabis industry. Its advantages include focus on pharmaceutical-grade APIs. Its disadvantages include a smaller market share and financial constraints compared to competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are not available due to the company's limited operating history.
Future Projections: Future growth projections require access to analyst estimates and company guidance. These are not available for the current date.
Recent Initiatives: Recent initiatives include manufacturing agreements and strategic partnerships aimed at expanding its market presence. Details are best found in company press releases.
Summary
Lucy Scientific Discovery Inc. is a relatively new company focused on the growing market of pharmaceutical-grade cannabinoid and psychedelic APIs. It has potential due to its specialized manufacturing capabilities and focus on quality. However, its limited operating history, reliance on regulatory approvals, and competition from established players present significant challenges. The company's long-term success will depend on its ability to secure partnerships, navigate the evolving regulatory landscape, and effectively market its products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lucy Scientific Discovery Inc.
Exchange NASDAQ | Headquaters Victoria, BC, Canada | ||
IPO Launch date 2023-02-09 | CEO & Executive Chair Mr. Richard D. Nanula | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2 | Website https://www.lucyscientific.com |
Full time employees 2 | Website https://www.lucyscientific.com | ||
Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.